Pacira Pharma (PCRX) Tops Q4 EPS by 12c, Revenue Beats; Offers FY20 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:01 AM EST Full-year 2019 revenue increases 25 percent to $421 million versus 2018
Total 2020 revenue guidance of between $485 million and $500 million
Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth
Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20... More
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:00 AM ESTFull-year 2019 revenue increases 25 percent to $421 million versus 2018 Total 2020 revenue guidance of between $485 million and $500 million Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20 percent growth, said Dave... More
